DATAIKU
According to research run by Dataiku, the platform for Everyday AI, the power of data and AI is becoming increasingly available to non-technical employees at companies across EMEA.
The survey, which was run across the United Kingdom, France, the Netherlands, Germany, and the United Arab Emirates, polled over 700 senior decision makers of companies actively using data science platforms and AI models across the enterprise.
It identified a growing trend of empowered non-technical users working with data and AI to make pivotal business decisions. Forty seven percent of EMEA leaders indicated that their non-technical business users have full access to data and AI to attain business goals, and a further 49% stated that business users have at least some access. Eighty four percent of these companies across EMEA said that they are using low- and no-code platforms to achieve these AI goals.
Dataiku Senior Vice President and General Manager, Gregory Herbert, commented: “We’ve seen a great shift in accessibility via the use of low- and no-code platforms, but for many companies, there’s still extensive untapped potential when it comes to making data and AI available to non-technical business users. What we really want to see is AI that is so ingrained and intertwined with the workings of the day-to-day that it’s just part of the business — not only being used or developed by data scientists. If enterprises want to see a deeper transformation and truly data-driven business results, Everyday AI must become a reality for non-data-focused roles.”
AI Drives Momentum Despite Economic Volatility
The majority of companies (79%) surveyed across EMEA indicated they are leveraging AI to its full capacity, and more than 80% of firms indicated that they are able to measure the ROI of their AI investments.
The survey also indicated continued momentum with AI across EMEA. While leaders indicated that business acceleration (50%) and staying ahead of the competition (36%) were the initial top reasons for investing in AI, 2023 has seen a marked shift in AI business goals. When asked what the top three business goals companies were looking to achieve with AI over the next five years, innovation won out (59%), followed by cost reduction (49%) and increased revenue (48%.)
How Will the European Union’s New AI Regulation Impact Business?
The upcoming EU AI regulation requires that any business that commercialises an AI system as a service or a product on the European market conduct a risk assessment to identify risks for all AI systems across the enterprise. This includes any risk surrounding data quality, transparency, human oversight, and accountability.
While there have been criticisms of the EU AI Act’s potential impact on AI innovation, the survey revealed that nearly 80% of respondents did not feel it would hinder innovation and, rather, would introduce new opportunities.
-ENDS-
About Dataiku
Dataiku is the platform for Everyday AI that allows companies to leverage one central solution to design, deploy, govern, and manage AI and analytics applications. Since its founding in 2013, the company has been the leader in democratizing data and empowering organization-wide collaboration. Today, more than 500 companies worldwide use Dataiku to integrate and streamline their use of data, analytics, and AI, driving diverse use cases from fraud detection and customer churn prevention, to predictive maintenance and supply chain optimization. Stay connected with us on our blog, Twitter (@dataiku) and on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
